BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioVisioN AG Signs Collaboration Agreement


10/19/2005 5:12:25 PM

HANNOVER, Germany, December 9 /PRNewswire/ -- The German biotech company BioVisioN AG today announced the closing of a service agreement with the Swiss pharmaceutical company Novartis Pharma AG. The agreement comprises the evaluation of clinical samples provided by Novartis using BioVisioN's proprietary Differential Peptide Display(R) technology. The aim is to find and identify clinically relevant peptides (small proteins). BioVisioN values the agreement as a further evidence for the capability and the increasing acceptance of their Peptidomics(R )-Technologies.

BioVisioN's Chief Business Officer Dr. Rainer Voegeli: "Thanks to our consequent development strategy we were able to establish highly sensitive and well reproducible technologies for the identification of peptide biomarkers and other pharmaceutically relevant peptides in the context of clinical studies and preclinical research that offer significant advantages compared to other existing approaches." BioVisioN AG specialises in the identification of disease-relevant peptides and proteins using Peptidomics(R) in order to discover new diagnostic markers, or biomarkers and therapeutic leads and targets. Apart from research collaborations, BioVisioN provides access to ist technology also in fee-for-service contracts as a Biological Research Organisation.

Pressekontakt: Dr. Rainer Voegeli, Head of Business Development BioVisioN AG Feodor-Lynen-Str. 5 30625 Hannove Fon: +49(0)511-538-896-0 Fax: +49(0)511-538-896-66 bd@biovision-discovery.dehttp://www.peptidomics.com/

BioVisioN AG

CONTACT: Pressekontakt: Dr. Rainer Voegeli, Head of BusinessDevelopment, BioVisioN AG, Feodor-Lynen-Str. 5, 30625 Hannover,Fon: +49(0)511-538-896-0, Fax: +49(0)511-538-896-66,bd@biovision-discovery.dehttp://www.peptidomics.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES